[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100150131":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":58,"collaborators":40,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":40,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":40,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":44,"whyStopped":40,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Gelb, Arthur F., M.D.","INDIV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Asthma observational study arm","OTHER","Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg\u002Fsalmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg\u002Fformoterol 4.5mcg bid)or Dulera 100-200mcg mometasone\u002F5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.",[13,14],"Drug: fluticasone\u002Fsalmeterol in all asthmatics","Drug: budesonide\u002Fformoterol or fluticasone\u002Fsalmeterol in all asthmatics",[16,24],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","fluticasone\u002Fsalmeterol in all asthmatics","budesonide 80ug\u002Fformoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug\u002Fsalmeterol 50ug, 1 inhalation bid X 20-60 days",[9],[22,23],"symbicort 80\u002F4.5","advair 100\u002F50 or 250\u002F50 or 500\u002F50 bid",{"type":17,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"budesonide\u002Fformoterol or fluticasone\u002Fsalmeterol in all asthmatics","budesonide 160ug\u002Fformoterol 4.5ug, 2 inhalations bid or fluticasone 250ug\u002Fsalmeterol 50ug, 1 inhalations bid",[9],[29,30],"symbicort 160\u002F4.5","advair 250\u002F50",[32],{"name":33,"affiliation":34,"role":35},"Arthur F Gelb, MD","Arthur F Gelb Medical Corporation","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","562-633-2204",null,"afgelb@msn.com",[43],{"facility":34,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Lakewood","California","90712","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-118.13396,33.85363,{"lat":54,"lon":53},[57],{"name":33,"role":35,"phone":40,"phoneExt":40,"email":40},{"type":35,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"Arthur F Gelb MD","Principal Investigator","100150131","phase-4-mechanisms-of-airflow-limitation-during-exacerbation-of-asthma-100150131",false,"NCT01225913","Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers","Inclusion Criteria:\n\n* Current non-smoking (\\\u003C10 pack yr smoking history)\n* Stable, treated asthmatics\n* Age 10-80 yr\n* post 180ug albuterol by MDI: FEV 1\u002FFVC \\\u003C 70% and FEV 1 \\\u003C80% predicted\n\nExclusion Criteria:\n\n* Pregnancy","ALL","10 Years","80 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and\u002For small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and\u002For loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.",[79],"Asthma",[81,82,83],"asthma","lung function","inflammation","2023-10-25",{"date":86,"type":87},"2023-10-26","ACTUAL",{"date":89,"type":40},"2007-10",{"date":91,"type":73},"2027-06",{"name":5,"class":6},1]